Zymeworks Inc 2025年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the transition period fromtoCommission file number:001-41535______________________________________ZYMEWORKS INC. (Exact name of registrant as specified in its charter) Indicate by check mark whether the registrant: (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject tosuch filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of1934).Yes☐No☒ The number of outstanding shares of common stock of the registrant, $0.00001 par value per share, as of August5, 2025 was75,166,196. ZYMEWORKS INC.QUARTERLY REPORT ON FORM 10-QFor the Quarter Ended June 30, 2025Table of Contents PART I. FINANCIAL INFORMATION Item 1.Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II. OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.Exhibits 35358585858586 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q includes “forward-looking statements” or information within the meaning of applicable securitieslegislation, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the SecuritiesExchange Act of 1934 as amended (the “Exchange Act”). Forward-looking statements include statements that may relate to our plans,objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other informationthat is not historical information. Many of these statements appear, in particular, under the headings “Business”, “Risk Factors” and“Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Forward-looking statements can often beidentified by the use of terminology such as “subject to,” “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “on track,”“project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions, or bydiscussions of strategy. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives,performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.In particular, these forward-looking statements include, but are not limited to, statements about: •the size of our addressable markets and our ability to commercialize product candidates;•the achievement of advances in and expansion of our therapeutic platforms and antibody engineering expertise;•the likelihood of product candidate development and clinical trial progression, initiation or success;•the evolution of our business strategy related to anticipated and potential future milestones and royalty streams and existingand potential new partnerships; and•our ability to predict and manage government regulation. All forward-looking statements, including, without limitation, those related to our examination of historical operating trends, are basedupon our current expectations and various assumptions. Certain assumptions made in preparing the forward-looking statementsinclude: •our ability to manage our growth effectively;•the absence of material adverse changes in our industry or the global economy;•our ability to understand and pre